The global infant nutrition industry is entering a new phase of transformation as stricter safety regulations drive reformulation, enhanced testing protocols, and increased transparency. A 2025 consumer research survey† underscores the growing importance of transparency and third-party validation in shaping purchasing decisions. A majority of global respondents (51%) report that professional certifications—such as cruelty-free designations and independently verified organic claims—either always or often influence their choices, reflecting a heightened demand for credibility and trust in product claims, according to GlobalData, a leading intelligence and productivity platform.
The introduction of the Infant Formula Safety Modernization Act in March 2026 marks a significant step toward strengthening regulatory oversight in the US, with a focus on pathogen testing, environmental monitoring, and faster reporting of contamination risks. This development reflects growing regulatory and consumer scrutiny following recent safety incidents, reinforcing the need for more robust quality assurance systems across the industry.
As safety expectations rise, manufacturers are increasingly prioritizing advanced testing technologies and stricter supply chain controls. This shift is influencing not only compliance strategies but also product development, as companies reformulate products to meet higher safety and quality benchmarks.
Mani Bhushan Shukla, Consumer Analyst at GlobalData, comments: “Infant nutrition is one of the most strictly regulated categories within FMCG, and recent developments are pushing companies to go beyond compliance and toward proactive risk management. Safety is no longer just a regulatory requirement—it is becoming a core differentiator that shapes product design, sourcing, and consumer trust.”
Regulatory pressure reshapes quality and compliance strategies
Recent incidents have accelerated regulatory action and industry response. In November 2025, US-based ByHeart initiated a voluntary recall following potential contamination risks, highlighting the importance of stringent monitoring systems. Earlier, Abbott Nutrition’s 2022 recall and subsequent supply disruption had already exposed vulnerabilities in the infant formula supply chain, prompting regulators and manufacturers to reassess safety frameworks.
In response, companies are investing in enhanced quality assurance and traceability systems. Brands such as Bobbie have positioned themselves around transparency and adherence to stringent manufacturing standards, while international manufacturers such as Kendamil have gained traction in the US market by emphasizing quality sourcing and compliance with rigorous European regulations.
GlobalData’s 2025 Q3 global consumer survey reveals that 62% of consumers indicate that health labeling, including clear information on protein, sugar, fiber, and carbohydrate content, consistently guides their purchasing behavior, signalling increased attention to nutritional awareness. Additionally, 52% of respondents state that allergen information plays a similarly influential role, highlighting the rising need for clear, accessible disclosures to support safer and more informed consumption†.
Shukla adds: “Collectively, these findings reinforce a broader shift toward informed decision-making, where transparency, accountability, and health considerations are central to consumer engagement.”
Innovation expands alongside safety requirements
At the same time, the category is witnessing continued innovation in formulation and ingredient sourcing. Danone and Nestlé have been advancing formula compositions with a focus on nutritional precision and safety, while newer entrants are exploring alternative approaches.
Else Nutrition, for example, has expanded its plant-based infant nutrition portfolio, targeting consumers seeking dairy-free alternatives while maintaining compliance with regulatory standards. These developments highlight how innovation and safety are evolving in parallel, rather than as competing priorities.
Shukla continues: “As regulatory frameworks tighten, companies face the challenge of balancing innovation with compliance. Reformulation efforts must ensure not only nutritional adequacy but also microbiological safety and consistency in production. This is particularly relevant for newer ingredient systems and alternative protein sources, which require additional validation to meet regulatory expectations.”
Shukla concludes: “The tightening of safety regulations is reshaping the competitive landscape in infant nutrition. Companies that invest in robust quality systems, transparent communication, and scientifically validated formulations will be better positioned to build long-term consumer trust. As the category evolves, safety and innovation will increasingly go hand in hand in defining product success.”
†GlobalData 2025 Q3 global consumer survey was conducted with 22,203 respondents across 42 countries.
